Name: Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade
SKU: PX-TA1297
Availability: InStock

Product name	Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade
Source	CAS 1000676-41-4
Species	Homo sapiens
Purity	>85%
Buffer	PBS buffer PH7.5
Delivery condition	Blue ice (+4°C)
Delivery Time	3-5 days if in stock; 3-5 weeks if production needed
Storage condition	store at -80°C
Brand	ProteoGenix
Aliases /Synonyms	Lirilumab,BMS-986015,IPH2102,KIRD2 subgroup,anti-KIRD2 subgroup
Reference	PX-TA1297
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype	Human IgG1
Clonality	Monoclonal Antibody

Description of Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade

General information on Anti-KIRD2 subgroup[Homo sapiens] (Lirilumab) Monoclonal Antibody

Lirilumab has been investigated for the treatment of Leukemia, Cancer, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia.

Publication

Furkan Yigitbilek, Elif Ozdogan, Nitin Abrol, Walter D. Park, Michael J. Hansen, Surendra Dasari, Mark D. Stegall and Timucin Taner,Liver mesenchymal stem cells are superior inhibitors of NK cell functions through differences in their secretome compared to other mesenchymal stem cells,Front. Immunol., 21 September 2022, Sec. Alloimmunity and Transplantation, https://doi.org/10.3389/fimmu.2022.952262

Reviews

There are no reviews yet.

Be the first to review “Lirilumab Biosimilar – Anti-KIRD2 subgroup mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Your rating *

In which application did you use the antibody? *

Did it work in your application? * Yes No

Your review *

Name *

Email *

Size

Clear

Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

KPTX233 1404$

View product

Send us a message from the form below